NEUMORA THERAPEUTICS

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Participate in Upcoming Conferences in November

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

29 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders

14 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation

20 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

07 May 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Participate in Upcoming Conferences in May

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

15 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days

13 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

07 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

22 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

12 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics to Participate in Upcoming Conferences in November

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development

10 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Neumora Therapeutics Announces Pricing of Initial Public Offering

14 Sep 2023 20:49:04 By Nasdaq GlobeNewswire